Skinvisible Licensee Receives Reorder from Walgreens

New First Aid Antiseptic Product Made with Invisicare Selling Nationwide

Las Vegas, NV- January 28, 2010 - Skinvisible, Inc.'s (SKVI:OTCBB) licensee, JD Nelson and Associates LLC, announced today that reorders have been received as a result of the successful launch last week of their new product Safe4Hours® First Aid Antiseptic Skin Protectant in over 7,000 Walgreens stores (NYSE:WAG). Re-orders have been received from eleven of twelve distribution centers. JD Nelson licensed Skinvisible's newly formulated first aid antiseptic lotion, a product which is formulated with the benefits of the Company's patented Invisicare® delivery system. Safe4Hours® First Aid Antiseptic Skin Protectant with Invisicare binds to the skin, resisting both wash off and perspiration while continuing to kill bacteria for up to four hours and longer (www.safe4hours.com).

"We are very pleased with JD Nelson's successful product launch with Walgreens, the nation's largest pharmacy chain," said Mr. Terry Howlett, President and CEO of Skinvisible Pharmaceuticals, Inc. "We anticipate further growth as their marketing campaign which includes print, radio and TV, ramps up over the next several weeks. We have recently shipped additional Invisicare polymer to fulfill their Walgreens re-order and we foresee continuous orders as they expand their distribution with additional mass merchandisers and pharmacy chains. Additionally, they are experiencing brisk sales of Safe4Hours skin protectant in Canada where it is available in Rexall, PharmaSave, Lawtons, Guardian and other pharmacy chains."

Safe4Hours® First Aid Antiseptic Skin Protectant helps to prevent infections by reducing a broad spectrum of bacteria, including MSRA on minor cuts, scrapes, and burns as well as protecting and relieving chaffed, chapped, cracked and dry skin. Safe4Hours promotes the healing process by allowing the skin to retain its natural moisture.

According to the Center for Disease Control (CDC), MRSA (methicillin-resistant Staphylococcus aureus), a staph infection that causes severe infections, can be found almost anywhere in the community. Of the 12 million annual doctor visits for skin infections, MRSA is the cause in more than half. MRSA can be spread through contact with infected skin, surfaces or personal items such as towels. The CDC recommends parents be vigilant about their children's hygiene. Initially just a hospital acquired infection, MRSA can now is commonly found in schools, dormitories, athletic facilities, military barracks, households, prisons, and daycares.

Skinvisible licenses its patented products worldwide to pharmaceutical, consumer goods and medical companies. License agreements can include R&D fees, upfront licensing fees, and on-going royalties, along with the sale of Invisicare, which is 5 to 8% of each finished formulation.

Invisicare is Skinvisible's patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives and reduce irritation. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants.   www.invisicare.com

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare.   www.skinvisible.com

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the quarter ending October 31, 2009).